Inside of a Legal Psilocybin Wellness Retreat
At Benzinga, we do what we say, and we say what we do. This hands-on mentality allowed me to take a week off to experience a legal psilocybin retreat in Jamaica.
The active ingredient in “magic mushrooms” is currently being researched by top-tier institutions for the treatment of severe mental health conditions such as major depression, addiction, and end-of-life distress.
Psilocybin can also be a great tool for wellbeing and human optimization. The wellness aspect of psilocybin treatment has recently opened the gates to psychedelic tourism, as a rapidly growing trend. But, however fast the psychedelics industry is moving forward, psilocybin continues to be illegal in most countries and jurisdictions.
/PRNewswire/ MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, announced the start of a study for its LSD.
Mind Medicine (MindMed) Inc launches Phase 1 study of potential LSD emergency off-switch ketanserin with University Hospital Basel s Liechti Lab proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
(NEO: MMED)MindMed (OTCQB: MMEDF) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company announced a new partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties. As part of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together..
Share this article
Share this article
ZUG, Switzerland, Feb. 11, 2021 /PRNewswire/ MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company announced a new partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties.
As part of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together. The first initial compounds have already been synthesized by MindShift Compounds AG and related patent applications were filed by MindMed. MindMed plans to begin first-in-human Phase 1 clinical trials as early as Q1 2022 through its existing clinical trial platform for psychedelic and empathogenic compounds in Switzerland.